Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 3/20 | 0.31 |
| ▸ | KDM4A | O75164 | 3/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.31 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612476 | 0.88 | CYP1A2 (0.40) | MEN1KMT2AKDM4EAGTR1AGTR2 | |
| SCHEMBL5359874 | 0.84 | MAPK8 (0.43) | KDM4EMAPK8 | |
| SCHEMBL5357847 | 0.83 | PTGER4 (0.38) | CCR2 | |
| SCHEMBL6804130 | 0.83 | MAPK8 (0.40) | KMT2AMAPK8 | |
| SCHEMBL5359315 | 0.83 | PTGER4 (0.39) | MEN1KMT2AKDM4EMAPK8 | |
| SCHEMBL6615388 | 0.82 | MAPK8 (0.47) | MEN1KMT2AKDM4EMAPK8 | |
| SCHEMBL6613628 | 0.81 | MAPK8 (0.39) | KDM4EMAPK8 | |
| SCHEMBL6613930 | 0.80 | CA2 (0.45) | MEN1KMT2AKDM4E | |
| SCHEMBL6615502 | 0.80 | MAPK8 (0.38) | KMT2AMAPK8 | |
| SCHEMBL6613045 | 0.80 | MAPK8 (0.38) | MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252157-B1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2004-06-23 | — | — | EP | claimed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | claimed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | claimed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1252157-B1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | disclosed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PDE12, PDE4A, PDE4B | GPBAR1 1129/4885MEN1 4650/4885KMT2A 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.